Welcome to our dedicated page for McKesson SEC filings (Ticker: MCK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
McKesson Corporation filings document operating results, capital structure, financing arrangements, governance matters, and registered securities for the healthcare services and pharmaceutical distribution company. Its 8-K reports include quarterly and annual results, financial guidance, share repurchase authorizations, dividend-related disclosures, and Regulation FD materials connected to earnings communications.
McKesson's SEC records also cover material credit agreements, including revolving credit facilities and subsidiary senior secured facilities, as well as executive officer transition disclosures and related arrangements. The filing record identifies NYSE-listed common stock and debt securities, including notes due 2026 and 2029, and includes a Form 25 notice for removal from listing and registration of notes due 2025.
McKesson Corporation Chief Executive Officer Brian S. Tyler reported an open-market sale of 8,463 shares of McKesson common stock on July 7, 2026 at an average price of $793.56 per share. The sale was made pursuant to a previously adopted trading plan dated December 15, 2025, in compliance with Rule 10b5-1(c), indicating it was pre-planned rather than a discretionary trade.
After this transaction, Tyler directly holds 5,919 shares of McKesson common stock. In addition, he has an indirect interest in 215.9211 shares held through the McKesson Corporation 401(k) Retirement Savings Plan. The filing shows a net-sell position for this report, with no derivative exercises disclosed.
McK filed a Form 144 reporting proposed sales of Common Stock tied to recent restricted stock vesting. The filing lists a restricted stock vesting date of 05/19/2026 and shows sale notifications with share counts and dollar amounts on 06/09/2026 and 06/17/2026.
The filing identifies Brian S. Tyler with two reported transactions: 4,929 shares on 06/09/2026 and 8,463 shares on 06/17/2026, with the document listing corresponding amounts of $3,760,827.00 and $6,559,925.19. A brokerage entry for Fidelity Brokerage Services LLC is also shown.
McKesson Corporation reported an upcoming leadership change in its strategy organization. On June 29, 2026, Executive Vice President and Chief Strategy and Business Development Officer Thomas L. Rodgers, a named executive officer, gave notice of his intention to retire from that role, with his last day of employment on August 1, 2026.
To support an orderly transition, McKesson appointed Ramesh Srinivasan as Executive Vice President, Chief Strategy Officer, effective August 1, 2026. The company framed this as a planned retirement with a designated successor to maintain continuity in its strategy leadership.
McKesson Corporation Chief Executive Officer Brian S. Tyler reported an open-market sale of company stock. On June 17, 2026, he sold 8,463 shares of McKesson common stock at an average price of $775.13 per share in a transaction classified as a non-derivative sale.
The sale was carried out under a Rule 10b5-1(c) trading plan that was previously adopted on December 15, 2025, meaning it was pre-arranged rather than timed opportunistically. Following this sale, Tyler directly holds 14,382 shares of McKesson common stock and indirectly holds 215.7571 shares through the McKesson Corporation 401(k) Retirement Savings Plan.
MCK affiliate reported proposed sale of Common Stock via a Form 144 notice. The filing identifies Brian S. Tyler as the reporting person and shows a sale dated 06/09/2026 of 4,929 shares of Common Stock for $3,760,827.00. The filing header is dated 06/17/2026.
McKesson Corporation is asking shareholders to vote at its virtual 2026 Annual Meeting on July 22, 2026. Items include electing 11 directors for one-year terms, ratifying Deloitte & Touche LLP as auditor for fiscal 2027, and approving executive compensation on an advisory basis.
The Board has combined the CEO and Chair roles under Brian S. Tyler and appointed Dominic J. Caruso as Lead Independent Director, while long‑time director Donald R. Knauss will retire under tenure and age limits. Ten of 11 nominees are independent, and 70% of independent nominees have served five years or less.
For fiscal 2026, McKesson reports total revenue of $403 billion, earnings per diluted share of $38.38, adjusted EPS of $39.11, operating profit of $6.4 billion, operating cash flow of $6.2 billion and free cash flow of $5.4 billion, reflecting a 12% revenue increase.
McKesson Corporation reports that certain subsidiaries, including McKesson Medical-Surgical Top Holdings, entered into an amendment to their credit agreement to provide a new $2,250.0 million senior secured Term B loan facility due 2032.
The Term B Loan Facility bears interest at the borrower’s option at either the Adjusted Term SOFR Rate plus 2.25% per year or the Base Rate plus 1.25% per year, with an initial selection of the SOFR-based option. The facility is secured by substantially all tangible and intangible assets of the borrower and certain material U.S. subsidiaries, which act as guarantors.
The credit agreement includes financial covenants, including a maximum total net leverage ratio and a minimum interest coverage ratio, both with customary cure rights. Other terms of the underlying credit agreement remain substantially the same except for changes made by this amendment.
McKesson Corporation’s Chief Executive Officer Brian S. Tyler reported an open-market sale of 4,929 shares of Common Stock at 763.00 per share on June 9, 2026, under a previously adopted Rule 10b5-1(c) trading plan. Following the sale, he directly holds 22,845 shares and has an additional 215.7489 shares held indirectly through the McKesson Corporation 401(k) Retirement Savings Plan.
MCK filing reports proposed sale of Common Stock tied to restricted stock vesting. The notice lists 2,181 shares vesting on 05/21/2026 and 2,748 shares vesting on 05/23/2026, with the broker shown as Fidelity Brokerage Services LLC.
The form is a notification of share disposition under the stock plan following vesting; timing and price of any open‑market sales are not stated in the provided excerpt.